Suppr超能文献

一项关于以初级保健为基础的慢性阻塞性肺疾病试验(索尔福德肺部研究)的普遍性以及霍桑效应存在情况的研究。

Study investigating the generalisability of a COPD trial based in primary care (Salford Lung Study) and the presence of a Hawthorne effect.

作者信息

Pate Alexander, Barrowman Michael, Webb David, Pimenta Jeanne M, Davis Kourtney J, Williams Rachael, Van Staa Tjeerd, Sperrin Matthew

机构信息

Farr Institute, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Real World Evidence and Epidemiology, GlaxoSmithKline, Uxbridge, UK.

出版信息

BMJ Open Respir Res. 2018 Oct 25;5(1):e000339. doi: 10.1136/bmjresp-2018-000339. eCollection 2018.

Abstract

INTRODUCTION

Traditional phase IIIb randomised trials may not reflect routine clinical practice. The Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) allowed broad inclusion criteria and followed patients in routine practice. We assessed whether SLS COPD approximated the England COPD population and evidence for a Hawthorne effect.

METHODS

This observational cohort study compared patients with COPD in the usual care arm of SLS COPD (2012-2014) with matched non-trial patients with COPD in England from the Clinical Practice Research Datalink database. Generalisability was explored with baseline demographics, clinical and treatment variables; outcomes included COPD exacerbations in adjusted models and pretrial versus peritrial comparisons.

RESULTS

Trial participants were younger (mean, 66.7 vs 71.1 years), more deprived (most deprived quintile, 51.5% vs 21.4%), more current smokers (47.5% vs 32.1%), with more severe Global initiative for chronic Obstructive Lung Disease stages but less comorbidity than non-trial patients. There were no material differences in other characteristics. Acute COPD exacerbation rates were high in the trial population (98.37th percentile).

CONCLUSION

The trial population was similar to the non-trial COPD population. We observed some evidence of a Hawthorne effect, with more exacerbations recorded in trial patients; however, the largest effect was observed through behavioural changes in patients and general practitioner coding practices.

摘要

引言

传统的IIIb期随机试验可能无法反映常规临床实践。索尔福德慢性阻塞性肺疾病研究(SLS COPD)采用了宽泛的纳入标准,并在常规实践中对患者进行随访。我们评估了SLS COPD是否能代表英格兰慢性阻塞性肺疾病患者群体以及是否存在霍桑效应的证据。

方法

这项观察性队列研究将SLS COPD常规治疗组(2012 - 2014年)中的慢性阻塞性肺疾病患者与来自临床实践研究数据链数据库的英格兰匹配的非试验慢性阻塞性肺疾病患者进行了比较。通过基线人口统计学、临床和治疗变量探讨了可推广性;结局包括调整模型中的慢性阻塞性肺疾病急性加重以及试验前与试验期间的比较。

结果

试验参与者更年轻(平均年龄,66.7岁对71.1岁),贫困程度更高(最贫困五分位数,51.5%对21.4%),当前吸烟者更多(47.5%对32.1%),慢性阻塞性肺疾病全球倡议分级更严重,但合并症比非试验患者少。其他特征没有实质性差异。试验人群中慢性阻塞性肺疾病急性加重率较高(第98.37百分位数)。

结论

试验人群与非试验慢性阻塞性肺疾病人群相似。我们观察到了一些霍桑效应的证据,试验患者中记录到的急性加重更多;然而,最大的效应是通过患者的行为改变和全科医生的编码实践观察到的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d053/6203022/3de1e3965e95/bmjresp-2018-000339f01.jpg

相似文献

1
Study investigating the generalisability of a COPD trial based in primary care (Salford Lung Study) and the presence of a Hawthorne effect.
BMJ Open Respir Res. 2018 Oct 25;5(1):e000339. doi: 10.1136/bmjresp-2018-000339. eCollection 2018.
3
Proton pump inhibitors for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev. 2020 Aug 25;8(8):CD013113. doi: 10.1002/14651858.CD013113.pub2.
4
Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility.
BMC Med Inform Decis Mak. 2015 Feb 7;15:8. doi: 10.1186/s12911-015-0132-z.
5
Impact of socioeconomic status on participation and outcomes in the Salford Lung Studies.
ERJ Open Res. 2020 Mar 16;6(1). doi: 10.1183/23120541.00193-2019. eCollection 2020 Jan.
6
Effectiveness efficacy trials in COPD: how study design influences outcomes and applicability.
Eur Respir J. 2018 Feb 21;51(2). doi: 10.1183/13993003.01531-2017. Print 2018 Feb.
8
Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
N Engl J Med. 2016 Sep 29;375(13):1253-60. doi: 10.1056/NEJMoa1608033. Epub 2016 Sep 4.
9
Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330. doi: 10.1164/rccm.201605-1014OC.
10
The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.
Pragmat Obs Res. 2017 Sep 20;8:175-181. doi: 10.2147/POR.S144157. eCollection 2017.

引用本文的文献

4
Gait-Adaptability Training in People With Hereditary Spastic Paraplegia: A Randomized Clinical Trial.
Neurorehabil Neural Repair. 2023 Jan;37(1):27-36. doi: 10.1177/15459683221147839. Epub 2023 Jan 25.
5
Extending the data collection from a clinical trial: The Extended Salford Lung Study research cohort.
NPJ Prim Care Respir Med. 2023 Jan 18;33(1):4. doi: 10.1038/s41533-022-00322-7.
6
Defining and evaluating the Hawthorne effect in primary care, a systematic review and meta-analysis.
Front Med (Lausanne). 2022 Nov 8;9:1033486. doi: 10.3389/fmed.2022.1033486. eCollection 2022.
7
Realising the full potential of data-enabled trials in the UK: a call for action.
BMJ Open. 2021 Jun 16;11(6):e043906. doi: 10.1136/bmjopen-2020-043906.
8
INTREPID: single- multiple-inhaler triple therapy for COPD in usual clinical practice.
ERJ Open Res. 2021 Jun 7;7(2). doi: 10.1183/23120541.00950-2020. eCollection 2021 Apr.
9
The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study.
Int J Chron Obstruct Pulmon Dis. 2021 Mar 10;16:629-642. doi: 10.2147/COPD.S291931. eCollection 2021.

本文引用的文献

1
A Tutorial on Multilevel Survival Analysis: Methods, Models and Applications.
Int Stat Rev. 2017 Aug;85(2):185-203. doi: 10.1111/insr.12214. Epub 2017 Mar 24.
3
Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial.
J Eval Clin Pract. 2018 Feb;24(1):258-261. doi: 10.1111/jep.12796. Epub 2017 Jul 7.
4
Transportability of Trial Results Using Inverse Odds of Sampling Weights.
Am J Epidemiol. 2017 Oct 15;186(8):1010-1014. doi: 10.1093/aje/kwx164.
5
Streamlining cardiovascular clinical trials to improve efficiency and generalisability.
Heart. 2017 Aug;103(15):1156-1162. doi: 10.1136/heartjnl-2017-311191. Epub 2017 Apr 28.
6
Real-World Evidence - What Is It and What Can It Tell Us?
N Engl J Med. 2016 Dec 8;375(23):2293-2297. doi: 10.1056/NEJMsb1609216.
7
Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
N Engl J Med. 2016 Sep 29;375(13):1253-60. doi: 10.1056/NEJMoa1608033. Epub 2016 Sep 4.
8
Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records.
PLoS One. 2016 Mar 9;11(3):e0151357. doi: 10.1371/journal.pone.0151357. eCollection 2016.
9
Understanding the Hawthorne effect.
BMJ. 2015 Sep 4;351:h4672. doi: 10.1136/bmj.h4672.
10
Data Resource Profile: Clinical Practice Research Datalink (CPRD).
Int J Epidemiol. 2015 Jun;44(3):827-36. doi: 10.1093/ije/dyv098. Epub 2015 Jun 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验